Inhibitors of EZH2 methyltransferase activity have been demonstrated to selectively suppress the growth of diffused large B cell lymphoma (DLBCL) cells with gain-of-function mutations in EZH2, while exhibiting very limited effects on the growth of DLBCL cells with wild-type EZH2. Given that EZH2 is often overexpressed but not mutated in solid tumors, it is important to investigate the determinants of sensitivity of solid tumor cells to EZH2 inhibitors. In the current study, we show that three-dimensional (3D) culture of epithelial ovarian cancer (EOC) cells that overexpress EZH2 sensitizes these cells to EZH2 methyltransferase inhibition. Treatment of EOC cells with GSK343, a specific inhibitor of EZH2 methyltransferase, decreases the level...
It was suggested that the enhancer of zeste homolog 2 (EZH2) gene is a putative candidate oncogene i...
Abstract Background Many cancers show aberrant silenc...
Enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of Polycomb repressive complex 2 (PRC2...
Inhibitors of EZH2 methyltransferase activity have been demonstrated to selectively suppress the gro...
EZH2 is the catalytic subunit of polycomb repressive complex 2 (PRC2), which generates a methylation...
SummaryThe histone methyltransferase enhancer of Zeste homolog 2 (EZH2) is a candidate oncogene due ...
Ezh2 protein is the enzymatic component of the Polycomb Repressive Complex (PRC)-2, which represses ...
Enhancer of Zeste homolog 2 (EZH2) is involved in epigenetic regulation of gene transcription by cat...
Background: EZH2 is a histone methyltransferase (HKMT) responsible for the maintenance of epigenetic...
The histone methyltransferase EZH2 plays a role in maintenance of the stem component of cancer, and ...
ARID1A, a chromatin remodeler, shows one of the highest mutation rates across many cancer types. Not...
BACKGROUND: Glioblastoma (GBM) is the most lethal and aggressive malignant primary brain tumor in ad...
The Polycomb epigenetic silencing protein EZH2 is affected by gain-of-function somatic mutations in ...
Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the polycomb repressive complex 2 (PR...
enhancer of zeste homolog 2 (eZH2) has been found to be overexpressed in ovarian and other cancers a...
It was suggested that the enhancer of zeste homolog 2 (EZH2) gene is a putative candidate oncogene i...
Abstract Background Many cancers show aberrant silenc...
Enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of Polycomb repressive complex 2 (PRC2...
Inhibitors of EZH2 methyltransferase activity have been demonstrated to selectively suppress the gro...
EZH2 is the catalytic subunit of polycomb repressive complex 2 (PRC2), which generates a methylation...
SummaryThe histone methyltransferase enhancer of Zeste homolog 2 (EZH2) is a candidate oncogene due ...
Ezh2 protein is the enzymatic component of the Polycomb Repressive Complex (PRC)-2, which represses ...
Enhancer of Zeste homolog 2 (EZH2) is involved in epigenetic regulation of gene transcription by cat...
Background: EZH2 is a histone methyltransferase (HKMT) responsible for the maintenance of epigenetic...
The histone methyltransferase EZH2 plays a role in maintenance of the stem component of cancer, and ...
ARID1A, a chromatin remodeler, shows one of the highest mutation rates across many cancer types. Not...
BACKGROUND: Glioblastoma (GBM) is the most lethal and aggressive malignant primary brain tumor in ad...
The Polycomb epigenetic silencing protein EZH2 is affected by gain-of-function somatic mutations in ...
Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the polycomb repressive complex 2 (PR...
enhancer of zeste homolog 2 (eZH2) has been found to be overexpressed in ovarian and other cancers a...
It was suggested that the enhancer of zeste homolog 2 (EZH2) gene is a putative candidate oncogene i...
Abstract Background Many cancers show aberrant silenc...
Enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of Polycomb repressive complex 2 (PRC2...